Nutritional Intervention for Age-Related Muscular Function and Strength Losses

针对与年龄相关的肌肉功能和力量损失的营养干预

基本信息

  • 批准号:
    9515437
  • 负责人:
  • 金额:
    $ 9.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Sarcopenia, defined as age related loss of muscle mass and muscle function and strength, is very prevalent among the elderly. Sarcopenia is one of the largest public health problems facing a rapidly increasing, aging population in the United States and leads to increased incidence of falls, fractures and associated morbidities. Previous observations from our laboratory, as well as from many other laboratories, have demonstrated the efficacy of 2-hydroxy-2-methylbutyrate (HMB) alone or in combination with other amino acids in enhancing muscle strength and function in young athletes. We have recently demonstrated that the combination of HMB with two other amino acids, arginine and lysine, was effective in increasing muscle mass in elderly men and women during a year-long prospective study. When analyzing the data (Preliminary Results), we demonstrated a close correlation between the levels of 25-OH Vitamin D3 in this population and the level of improvement in muscle strength. We noted that individuals with plasma 25-OH Vitamin D3 levels >30 ng/ml manifested muscle strength gains supplemented with HMB and two amino acids, while those with plasma 25- OH Vitamin D3 of <30 ng/ml did not. These data form the basis of our current hypothesis that the combination of HMB and Vitamin D supplementation will be synergistic and will result in significant enhancements in overall muscle strength, function and muscle mass. We propose these Phase I and Phase II studies to prove our hypothesis. The Phase I study will test the short-term (12-wk) efficacy of a combination of HMB and Vitamin D to prevent and reverse muscle sarcopenia and the associated losses of muscular strength and functionality in older adults. We plan to recruit 100 men and women who will be assigned to one of four dietary treatments: (1) Control; (2) HMB (calcium salt), 3.0 g/day; (3) 2,000 IU Vitamin D; and (4) HMB, 3.0 g/d + 2,000 IU Vitamin D. The subjects will undergo a 3-day per week exercise program, and body composition and strength will be measured at four week intervals. We expect to demonstrate the synergy between HMB and Vitamin D in this short study. Phase II will test the long-term (12-mos) efficacy of this synergistic combination of HMB and Vitamin D on the enhancement of muscle strength and functionality in the elderly, thus leading to improved quality of life. Phase II will include an exercise arm just like Phase I, but will also include a non-exercise arm because many elderly adults do not participate in an exercise program. In addition to body composition and function and strength data, muscle biopsies will be obtained and muscle fiber and proteomic analysis will be performed. We anticipate that the data generated will lead to further research looking at mechanism(s) involved in loss of muscle and muscle function in the elderly. Improvement in muscle strength and muscle function as well as improvements in body composition over the year-long study will be used to market a product containing HMB and Vitamin D.
描述(由申请人提供):肌少症被定义为与年龄相关的肌肉质量、肌肉功能和力量的损失,在老年人中非常普遍。肌肉减少症是美国人口迅速增长和老龄化所面临的最大公共卫生问题之一,导致跌倒、骨折和相关疾病的发生率增加。我们实验室以及许多其他实验室之前的观察结果已经证明,2-羟基-2-甲基丁酸 (HMB) 单独使用或与其他氨基酸结合使用可有效增强年轻运动员的肌肉力量和功能。我们最近在一项为期一年的前瞻性研究中证明,HMB 与其他两种氨基酸(精氨酸和赖氨酸)的组合可有效增加老年男性和女性的肌肉质量。在分析数据(初步结果)时,我们证明了该人群中 25-OH 维生素 D3 的水平与肌肉力量的改善水平之间存在密切相关性。我们注意到,血浆 25-OH 维生素 D3 水平 >30 ng/ml 的个体在补充 HMB 和两种氨基酸后表现出肌肉力量增强,而血浆 25-OH 维生素 D3 <30 ng/ml 的个体则没有。这些数据构成了我们当前假设的基础,即 HMB 和维生素 D 补充剂的组合将具有协同作用,并将导致整体肌肉力量、功能和肌肉质量的显着增强。我们提出这些第一阶段和第二阶段研究来证明我们的假设。 I 期研究将测试 HMB 和维生素 D 组合预防和逆转老年人肌肉减少症以及相关肌肉力量和功能丧失的短期(12 周)功效。我们计划招募 100 名男性和女性,他们将被分配接受四种饮食治疗之一:(1)对照; (2)HMB(钙盐),3.0克/天; (3) 2,000国际单位维生素D; (4) HMB,3.0 克/天 + 2,000 IU 维生素 D。受试者将接受每周 3 天的锻炼计划,每隔 4 周测量一次身体成分和力量。我们希望在这项简短的研究中证明 HMB 和维生素 D 之间的协同作用。第二阶段将测试 HMB 和维生素 D 的这种协同组合在增强老年人肌肉力量和功能方面的长期(12 个月)功效,从而提高生活质量。第二阶段将像第一阶段一样包括一个运动臂,但也将包括一个非运动臂,因为许多老年人不参加运动计划。除了身体成分、功能和力量数据外,还将获得肌肉活检并进行肌肉纤维和蛋白质组分析。我们预计生成的数据将导致进一步研究老年人肌肉和肌肉功能丧失的机制。经过一年的研究,肌肉力量和肌肉功能的改善以及身体成分的改善将用于销售含有 HMB 和维生素 D 的产品。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Long-term Effects of Calcium β-Hydroxy-β-Methylbutyrate and Vitamin D3 Supplementation on Muscular Function in Older Adults With and Without Resistance Training: A Randomized, Double-blind, Controlled Study.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John A Rathmacher其他文献

John A Rathmacher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John A Rathmacher', 18)}}的其他基金

2-HOBA for Treatment of Pulmonary Hypertension
2-HOBA 治疗肺动脉高压
  • 批准号:
    10698621
  • 财政年份:
    2021
  • 资助金额:
    $ 9.77万
  • 项目类别:
Efficacy of an Electrophile Scavenger in the Prevention of Gastrointestinal Inflammatory Carcinogenesis
亲电子清除剂在预防胃肠道炎症癌发生中的功效
  • 批准号:
    10257862
  • 财政年份:
    2021
  • 资助金额:
    $ 9.77万
  • 项目类别:
2-HOBA for Treatment of Pulmonary Hypertension
2-HOBA 治疗肺动脉高压
  • 批准号:
    10257863
  • 财政年份:
    2021
  • 资助金额:
    $ 9.77万
  • 项目类别:
2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans
2-羟基苄胺预防阿尔茨海默病:对人类的初步评估
  • 批准号:
    9970647
  • 财政年份:
    2016
  • 资助金额:
    $ 9.77万
  • 项目类别:
2-Hydroxybenzylamine for the prevention of Alzheimer's disease: Initial evaluation in humans
2-羟基苄胺预防阿尔茨海默病:对人类的初步评估
  • 批准号:
    9564351
  • 财政年份:
    2016
  • 资助金额:
    $ 9.77万
  • 项目类别:
Gamma-ketoaldehyde scavengers for alcoholic liver disease
γ-酮醛清除剂治疗酒精性肝病
  • 批准号:
    8834691
  • 财政年份:
    2014
  • 资助金额:
    $ 9.77万
  • 项目类别:
Nutritional Intervention for Age-Related Muscular Function and Strength Losses
针对与年龄相关的肌肉功能和力量损失的营养干预
  • 批准号:
    7909359
  • 财政年份:
    2010
  • 资助金额:
    $ 9.77万
  • 项目类别:
Nutritional Intervention for Age-Related Muscular Function and Strength Losses
针对与年龄相关的肌肉功能和力量损失的营养干预
  • 批准号:
    8775460
  • 财政年份:
    2010
  • 资助金额:
    $ 9.77万
  • 项目类别:
Adjuvant Nutrition for Critically III Trauma Patients
危重 III 级创伤患者的辅助营养
  • 批准号:
    6582697
  • 财政年份:
    2003
  • 资助金额:
    $ 9.77万
  • 项目类别:
BODY PROTEIN METABOLISM & NUTRITION IN AIDS WASTING
身体蛋白质代谢
  • 批准号:
    6977108
  • 财政年份:
    2003
  • 资助金额:
    $ 9.77万
  • 项目类别:

相似国自然基金

基于年龄和空间的非随机混合对性传播感染影响的建模与研究
  • 批准号:
    12301629
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
多氯联苯与机体交互作用对生物学年龄的影响及在衰老中的作用机制
  • 批准号:
    82373667
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
母传抗体水平和疫苗初种年龄对儿童麻疹特异性抗体动态变化的影响
  • 批准号:
    82304205
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    青年科学基金项目
年龄结构和空间分布对艾滋病的影响:建模、分析与控制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
随机噪声影响下具有年龄结构的布鲁氏菌病动力学行为与最优控制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

The Influence of Lifetime Occupational Experience on Cognitive Trajectories Among Mexican Older Adults
终生职业经历对墨西哥老年人认知轨迹的影响
  • 批准号:
    10748606
  • 财政年份:
    2024
  • 资助金额:
    $ 9.77万
  • 项目类别:
The Proactive and Reactive Neuromechanics of Instability in Aging and Dementia with Lewy Bodies
衰老和路易体痴呆中不稳定的主动和反应神经力学
  • 批准号:
    10749539
  • 财政年份:
    2024
  • 资助金额:
    $ 9.77万
  • 项目类别:
Understanding the Mechanisms and Consequences of Basement Membrane Aging in Vivo
了解体内基底膜老化的机制和后果
  • 批准号:
    10465010
  • 财政年份:
    2023
  • 资助金额:
    $ 9.77万
  • 项目类别:
Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy
TASIS-花生(皮肤内靶向过敏原特异性免疫疗法)贴剂治疗花生过敏的安全性和耐受性
  • 批准号:
    10551184
  • 财政年份:
    2023
  • 资助金额:
    $ 9.77万
  • 项目类别:
Sustained eIF5A hypusination at the core of brain metabolic dysfunction in TDP-43 proteinopathies
持续的 eIF5A 抑制是 TDP-43 蛋白病脑代谢功能障碍的核心
  • 批准号:
    10557547
  • 财政年份:
    2023
  • 资助金额:
    $ 9.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了